Healthcare / Medical Instruments & SuppliesTokyo
$1207.00
-8.00 (-0.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.6B · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$48.3B
P/E
12.4x
↓EV/EBITDA
6.2x
↓ROE
20.8%
↑Gross Margin
67.7%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+5.0%
FCF CAGR
+13.1%
FCF margin
25.5%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.30B · net income $3.79B · FCF $2.62B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $10.30B | $10.30B | $10.08B | $9.35B |
| Net Income | $3.79B | $3.79B | $3.97B | $3.37B |
| EBITDA | $5.92B | $5.92B | $6.17B | $5.27B |
| EPS | 94.70 | 94.70 | 99.30 | 84.25 |
| Gross Margin | 67.7% | 67.7% | 69.8% | 71.6% |
| Operating Margin | 56.1% | 56.1% | 58.7% | 54.9% |
| Net Margin | 36.8% | 36.8% | 39.4% | 36.1% |
| Balance Sheet | ||||
| Current Ratio | 11.99 | 11.99 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $2.62B | $2.62B | $4.42B | $2.05B |
| Returns | ||||
| ROE | 20.8% | 20.8% | 24.7% | 23.9% |
| Valuation | ||||
| P/E | 12.39 | 12.39 | — | — |
| EV/EBITDA | 6.22 | 6.22 | — | — |
| P/B | 2.65 | 2.65 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 2.2% | 2.2% | 7.8% | — |
| EPS Growth | -4.6% | -4.6% | 17.9% | — |
| Dividend Yield | 6.8% | 6.8% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
4.2%
EPS terminal req.
$107.10
Spread vs growth
-8.8%
5Y implied EPS CAGR
6.5%
EPS terminal req.
$129.59
Spread vs growth
-11.1%
10Y implied EPS CAGR
8.2%
EPS terminal req.
$208.71
Spread vs growth
-12.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.6%
Start / end P/E
18.2x → 12.7x
EPS bridge
99.30 → 94.70
Residual
+1.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.